FNAM (Evolutionary Genomics) EBITDA Margin %: 0.00% (As of Dec. 2022)


FNAM Evolutionary Genomics Inc FNAM
31 GF Score
Price $0.00
View Full Analysis

What is Evolutionary Genomics EBITDA Margin %?

Evolutionary Genomics FNAM 31 EBITDA Margin % is 0.00% as of Dec. 2022. GuruFocus rates FNAM with a GF Score™ of 31/100.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Evolutionary Genomics's EBITDA for the three months ended in Dec. 2022 was $-0.16 Mil. Evolutionary Genomics's Revenue for the three months ended in Dec. 2022 was $0.00 Mil. Therefore, Evolutionary Genomics's EBITDA margin for the quarter that ended in Dec. 2022 was 0.00%.

Evolutionary Genomics  (OTCPK:FNAM) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Evolutionary Genomics EBITDA Margin % Related Terms

Evolutionary Genomics EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Evolutionary Genomics's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Evolutionary Genomics EBITDA Margin % Chart

Evolutionary Genomics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -692.17 -596.75 -19,000.00 0.00 0.00

Evolutionary Genomics Quarterly Data
Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

FNAM vs BXRX, GNCA, XSNX: EBITDA Margin % Comparison

For the Biotechnology subindustry, Evolutionary Genomics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Evolutionary Genomics EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Evolutionary Genomics's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Evolutionary Genomics's EBITDA Margin % falls into.


FNAM
31GF Score
Evolutionary Genomics Inc FNAM
EBITDA Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Evolutionary Genomics EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Evolutionary Genomics's EBITDA Margin % for the fiscal year that ended in Dec. 2022 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2022 )/Revenue (A: Dec. 2022 )
=-0.993/0
= %

Evolutionary Genomics's EBITDA Margin % for the quarter that ended in Dec. 2022 is calculated as

EBITDA Margin %=EBITDA (Q: Dec. 2022 )/Revenue (Q: Dec. 2022 )
=-0.157/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of 0.00% mean?
Evolutionary Genomics (FNAM) has a EBITDA Margin % of 0.00% as of Dec. 2022. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Evolutionary Genomics and its competitors.
Is Evolutionary Genomics' EBITDA Margin % too high?
Evolutionary Genomics' current EBITDA Margin % is 0.00%. Overall, Evolutionary Genomics has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Evolutionary Genomics' EBITDA Margin % compare to BXRX and GNCA?
Evolutionary Genomics' EBITDA Margin % of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Evolutionary Genomics and its competitors. Evolutionary Genomics's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Evolutionary Genomics stock overvalued right now?
Evolutionary Genomics (FNAM) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Evolutionary Genomics' overall GF Score™ is 31/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Evolutionary Genomics (FNAM), the current EBITDA Margin % is 0.00% as of Dec. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Evolutionary Genomics Business Description

Address 4220 Morning Star Drive, Castle Rock, CO, USA, 80108
Evolutionary Genomics Inc is involved in the development of a technology platform, the Adapted Traits Platform (ATP), to identify commercially valuable genes that control important traits in animals and plants. It uses the ATP to identify genes to improve crop plant traits such as yield, sugar content, biomass, drought tolerance, and pest/disease resistance. The company's platform identifies key genes that have changed successfully to impart new or improved traits. Its primary source of revenue had been contract services revenue for research performed by it on behalf of other commercial entities and grant income received from governmental agencies, industry associations and grant-making foundations for research performed.
31GF Score

Get the complete analysis for FNAM

EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price